Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-κB inhibition and p53 reactivation in human lung cancer cells.

@article{Zhou2013DeubiquitinaseIO,
  title={Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-κB inhibition and p53 reactivation in human lung cancer cells.},
  author={Binhua P. Zhou and Yinglin Zuo and Baojian Li and Hao Wang and Hao Liu and Xianfeng Wang and Xu Qiu and Yun Hu and Shijun Wen and Jun Du and Xianzhang Bu},
  journal={Molecular cancer therapeutics},
  year={2013},
  volume={12 8},
  pages={1381-92}
}
Proteasome inhibitors have been suggested as potential anticancer agents in many clinical trials. Recent evidence indicates that proteasomal deubiquitinase (DUB) inhibitors, bearing a different mechanism from that of traditional proteasome inhibitors, would be appropriate candidates for new anticancer drug development. In the present study, we describe the… CONTINUE READING